IFNα and IFNβ directly act on host hematopoietic cells, resulting in tumor inhibition, whereas IFNγ promotes tumor recognition by upregulating the MHC class I pathway, leading to enhanced T cell activation [107,108]. The gene discussed is IFNB1; the disease is neoplasm.